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Abstract Copper is one of the most interesting
elements for various biomedical applications. Copper
compounds show vast array of biological actions,
including anti-inflammatory, anti-proliferative, bio-
cidal and other. It also offers a selection of radioiso-
topes, suitable for nuclear imaging and radiotherapy.
Quick progress in nanotechnology opened new possi-
bilities for design of copper based drugs and medical
materials. To date, copper has not found many uses in
medicine, but number of ongoing research, as well as
preclinical and clinical studies, will most likely lead to
many novel applications of copper in the near future.
Keywords Copper  Nuclear medicine 
Nanotechnology  Drug development
Introduction
Copper (Cu) is a transition metal with atomic
number 29, known since ancient times. It is an
important trace element for most organisms in all
kingdoms. In humans, copper plays role as a
cofactor for numerous enzymes, such as Cu/Zn-
superoxide dismutase, cytochrome c oxidase,
tyrosinase, ceruloplasmin and other proteins, cru-
cial for respiration, iron transport and metabolism,
cell growth, hemostasis (Puig and Thiele 2002;
Bertini et al. 2010). With the progress in medical
sciences, copper has gained a lot of attention. The
number of publications concerning copper and its
compounds for potential medical applications,
have reached tens of thousands. There are several
reasons that render this element so attractive for
drug development. Generally, simple inorganic
salts of copper are toxic, but as a transition metal,
with unsaturated d shell, it forms a large number of
complexes. Coordination chemistry of copper is
well-studied and ‘‘straightforward’’ in comparison
to many other elements. From three known oxida-
tion states, ?1 and ?3 are mostly unstable in
biological systems, but on ?2 state, Cu forms
stable complexes with coordination number of 4, 5
or 6. Administration of copper in a form of
organometallic complexes can be done in order
to selectively deliver copper ions or radionuclides
to diseased tissues, or to modify pharmacokinetics
and/or pharmacodynamics of ligands. Moderate
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amounts of metal ions that could be liberated from
biological degradation or transchelation of Cu
complexes can be managed by organism, as copper
is an important microelement, in contrary to many
other transition metals, whose leakage from their
compounds can lead to accumulation and toxic
effects. Copper has several radioisotopes, five of
them are particularly interesting for radiotherapy
and imaging applications. Continuous progress of
nanotechnology made it possible to exploit novel
physicochemical properties of copper-containing
nanoparticles and molecules. This article reviews
current trends in various fields of medicine, in
development of copper based pharmaceuticals and
medical materials.
Biological activity of complexes of stable copper
isotopes
Inflammation
In folklore it is believed that wearing copper brace-
lets and jewellery can ease the pain in rheumatoid
arthritis. This belief had drawn attention to possible
anti-inflammatory properties of copper ions and
complexes. This issue was extensively researched
in past century by Sorenson (1976, 1982, 1987,
1989). Hosty´nek et al. (2006) found that metallic
copper can indeed penetrate skin, after being oxi-
dized on air. Anti-inflammatory effect of Cu can be
linked with modulation of prostaglandin synthesis
(Sakuma et al. 1996; Franco and Doria 1997; Sakuma
et al. 1999), interleukin IL-2 expression (Hopkins
and Failla 1999), neutralization of reactive oxygen
radicals by Cu/Zn-superoxide dismutase and other.
Though copper deficiency is known to impair
immunity, the exact mechanism is unclear (Huang
and Failla 2000).
In the past decade, several authors reported
copper(II) complexes with potential anti-inflamma-
tory properties. For treatment of rheumatoid arthri-
tis, chelating agents that can facilitate transport of
Cu(II) ions to sites of inflammation were researched
(1–13).
Jackson et al. (2000) attempted to design linear
polyamine ligands that can mobilize copper in organism.
The complexes cannot be too stable, because they would
be quickly excreted with urine in unchanged form.
Ligands 1–4 formed neutral complexes only above pH
7.0 and were too labile for systemic administration, but
still could be used to facilitate dermal absorption of
copper. Complexes of 5–8, due to additional nitrogen
atom were significantly more stable (*2 log units), 6–8
were also more lipophilic, but the stability was still
suboptimal (Jackson et al. 2000). More promising results
for dermally absorbed Cu complexes were achieved for
ligands 9 and 10. The compounds show selectivity
towards copper ions, good stability at physiological pH
(formation constants at 25 C in 0.15 M NaCl, for
unprotonated ligands: log b = 11.51 for 9 and 18.62 for
10), low renal clearance and water/octanol partitioning
indicating possible dermal absorption. An important
feature of 9 and 10 is that they form more labile
complexes with Ca2? and Zn2? ions (for 9 and 10
respectively: with zinc log b = 5.55 and 11.51, with
calcium log b = 3.24 and 3.92), which are main
competitors of copper in blood plasma. Simulations
showed that Cu complexes of the ligands are stable in
blood plasma, and effectively mobilize copper ions
without affecting significantly other metal ions levels
(Zvimba and Jackson 2007). Odisitse et al. (2007, 2009)
also reported dermally absorbed complexes of copper
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with 11–13 ligands. The compounds showed approxi-
mately 24 h biological half-life which is desired for
potential anti-inflammatory drugs. Simulation of behav-
ior of 13 in blood plasma indicated that Ca2? and Zn2?
ions concentration is sufficient to compete with Cu2?,
even though 13 is more selective towards cupric ions.
Therefore, the ligand can facilitate copper transport
through skin, then release Cu2? ions in bloodstream.
Copper-zinc-superoxide dismutase (SOD) is an
important enzyme protecting cells against oxidative
injury, scavenging and neutralizing reactive oxygen
species. It has been shown that SOD can signifi-
cantly reduce inflammation induced in laboratory
animals (Emerit et al. 1991; Zhang et al. 2002;
Garcia-Gonza´lez et al. 2009). Many complexes of
copper(II) have similar to SOD ability to neutralize
superoxides (14–27). These SOD-mimicking com-
plexes of copper were proposed as non-analgesic
anti-inflammatory drugs by various authors: Cu
complexes of aromatic acids (14–16) (Suksrichavalit
et al. 2008), saccharinate and pyridine derivates (17–
18) (Ferrer et al. 2010), tolfenamic acid (19)
(Kovala-Demertzi et al. 2004), 2-amino-2-thiazoline
and polyamines (20–25) (Pontiki et al. 2006),
o-vanillin (26) (Gonza´lez-Baro´ et al. 2010), oxap-
rozinate (27) (Dutta et al. 2004).
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However, there is one important hindrance, as both
SOD and SOD-like Cu-complexes can cleave cellular
DNA by reacting with hydrogen peroxide and gener-
ating hydroxyl radicals by Fenton-type reaction (Sang
and Yang 2005; Han et al. 2007; Seng et al. 2009;
Ghosh et al. 2010; Ibrahim et al. 2011). This aspect
requires thorough dose–response studies, before this
group of potential anti-inflammatory drugs can
emerge.
In the last 20–30 years of 20th century, there was
a lot of interest in copper(II) complexes with
NSAIDs (Non-Steroidal Anti-Inflammatory Drugs),
such as acetylsalicylic acid, indomethacin, piroxi-
cam, ibuprofen, diclofenac, naproxen and others.
These complexes were reported to possess increased
activity and lower ulcerogenic effect than respective
NSAID and copper administered separately. How-
ever, none of the substances has been approved for
internal therapy of humans. Exhaustive review of the
subject was written by Weder et al. (2002) Cur-
rently, there are still a number of publications each
year on Cu-NSAIDs complexes, but mainly con-
cerning the structural and physicochemical aspects
of the compounds; structure–activity and biological
studies are sparse, therefore it can be assumed that
this group of potential drugs will not make any
impact on medicine in the nearest future.
It should be noted that copper-indomethacine
complex (28, Fig. 1) underwent some biological
evaluation, and is currently used in veterinary in
Australia, New Zealand and some other countries.
Similarly to other NSAID-Cu complexes, copper
indomethacinate retains parent drug anti-inflamma-
tory activity but have lower ulcerogenic effect,
probably due to free radical scavenging ability
(Bertrand et al. 1999). Cu-indomethacin-dimethyl-
formamide complex shows good solution stability
at pH 7.4 (\8 % decomposition after 3 days),
which can be further increased by micellar solu-
bilisation of the complex with Span 80 and
tetraglycol (Weder et al. 1999). In Australia, Cu-
salicylate was available until recently for external
use in humans, in a form of topical anti-inflamma-
tory gel.
Cancer
Since cisplatin was introduced for chemotherapy of
cancer, a search for other transition metal complexes
with anti-proliferative activity has started. Various
copper(II) complexes were found to be cytotoxic,
with the most common ligands being NSAIDs or
Schiff bases (29–38). As mentioned in above section,
many Cu(II) complexes possess catalytic activity
towards reactive oxygen species and can induce
breakage of DNA strand. This can explain cytotox-
icity of some of the compounds. 29 (Fig. 2) in
aqueous solution without presence of any external
reducing factors, forms bis-(1,10-phenantroline)cop-
per(I) which oxidatively degrades nucleic acids
(Barcelo´-Oliver et al. 2007). However, in many
cases, probably more sophisticated mechanisms are
involved.
Meloxicam (30) and piroxicam (31, Fig. 3)
form stable in physiological pH Cu complexes
(K = 3.2 9 109 and 9.8 9 109 M-2 respectively)
that are able to strongly bind with DNA, disrupting
its structure and stopping transcription as a result
(Roy et al. 2006; Cini et al. 2007). Copper N-(2-
hydroxyacetophenone) glycinate (32) is an interest-
ing immunomodulatory agent, capable of inducing
apoptosis in multidrug-resistant cancer cells by
stimulating production of cytokines, such as inter-
feron c or TNF-a (Tumor Necrosis Factor a)
(Mookerjee et al. 2006). Guo et al. (2010) suggested
that salicylaldehyde-amino acid Schiff base copper
chelates (33, 34) trigger cancer cell’s apoptosis by
downregulation of overexpressed mutant type P53
protein.
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Disulfiram, a drug used in alcoholism treatment,
forms in vivo a copper complex (35) which acts as a
proteasome inhibitor, and selectively induces apopto-
sis in breast tumors (Chen et al. 2006). Disulfiram and
copper gluconate are currently under phase I trials for
treatment of solid tumors with metastases in liver
(ClinicalTrials.gov 2012). Compound 36 shows high
in vitro and in vivo activity towards MCF-7, PC3 and
HEK293 cell lines. Its proposed mode of action is
multidirectional and includes apoptosis induction via
caspase pathway, DNA fragmentation and antioxidant
enzymes inhibition. 36 is more effective than cisplatin
in breast tumor models (about 20-fold lower IC50) and
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Other type Cu(II) complexes with both antimicrobial
and antitumor properties were reported by Singh et al.
(2009)(37,38).
Antimicrobial
Copper, both in metallic form and in many chemical
compounds, possess antimicrobial activity, which was
already used by ancients. Cupric ions exhibit non-
specific biocidal activity, although weaker than silver.
Copper-silver electrolytic ionization systems are used in
many hospitals to decrease number of Legionella
residing in hot water pipes. Metals and alloys used in
orthopedic implants can be doped with copper ions, in
order to reduce risk of infection after prosthetic surgery.
The tradeoff is reduced to some extent corrosion
resistance of the resulting materials, but still on a
Fig. 2 Crystal structure of Cu-o-iodohippurate-1,10-phenantroline complex(29) (Barcelo´-Oliver et al. 2007) Data from Cambridge
Crystallographic Data Centre
Fig. 3 Copper piroxicam-
DMF complex crystal
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reasonable level (Wan et al. 2007). Due to non-specific
toxicity, for the use of copper as an antibacterial
therapeutic, the metal should be administered in a form
of complex compounds, rather than simple inorganic
salts. Nature of chelating agent, however, plays very
important role, as there can be no simple correlation
between antibacterial activity and complex stability
(Azenha et al. 1995). Many various Cu(II) complexes
with different ligands were reported to possess antibac-
terial and antifungal activity (39–48) (Go¨lcu¨ et al. 2005;
Shakir et al. 2006; Singh et al. 2008; Sreedaran et al.
2008; Kumar and Arunachalam 2009; Suksrichavalit
et al. 2009). Singh et al. (2008) utilized an approach to
use ligands which already have antimicrobial activity
and enhance it by complexation with copper (39–41).
Antihypertensive drug pindolol, when complexed with
Cu (41) (complex stability constant log b = 11.28 in
water-dioxan 40:60 at 25 C), exhibits notable antimi-
crobial activity towards some bacterial and fungal strains
(Go¨lcu¨ et al. 2005). Water soluble, polymeric complex
47 shows good antimicrobial activity and is also capable
of binding DNA (Kumar and Arunachalam 2009).
The complexes (39–48) were only screened for antibi-
otic properties, and to the best of our knowledge no
further evaluations for medical applicability were per-
formed.
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Other uses
Copper (I)-Cl-(nicotinic acid)2 (polymeric) is able to
notably reduce gastrointestinal mucosa lesion caused
by NSAIDs such as acetylsalicylic acid. The complex
shows antioxidative, antiapoptotic, secretolytic and
antihemorrhagic activity and can be a good alternative
for currently used anti-ulcer drugs, proton pump
inhibitors, which increase gastrin level (Tuorkey and
Abdul-Aziz 2009). It is also a rare example of
Cu(I) compound proposed for medical use. Toyota
et al. (2005) described a series of copper and iron
complexes acting as thrombin inhibitors. One of these
compounds, Cu(II) complex with 4-formyl-3-hydro-
xybenzamidine and D-tryptophane (49), had the high-
est inhibitory activity (Ki value 2.7 9 10
-8 M),
comparable to registered anticoagulant drug, argatro-
ban (Ki 1.9 9 10
-8 M) (Toyota et al. 2005). Tian et al.
(2009) suggested copper-taurine as possible com-
pound able to facilitate wounds healing by stimulating
process of tissue regeneration and by preventing
infections.
Fig. 4 Crystal structure of




1096 Biometals (2012) 25:1089–1112
123
Work by Sylla-Iyarreta Veitı´a et al. (2009) is a good
example, how complexation with copper of clinically
used drug, valproic acid in that case, can lead to novel,
more potent compound. Bis-valproinato(1,10-phenan-
throline)copper(II) (50) was found to be very effective
in preventing Minimal Clonic seizures (ED50 8 lmol/kg).
1,10-phenantroline and salicylate Cu complex (51,
Fig. 4) and bis(1,10-phenanthroline)-l-bis(salicyla-
to)dicopper(II) with anticonvulsant activity effective
against MES (maximal electroshock) induced sei-
zures, were reported earlier by Lemoine et al. (2002).
Despite different structure in solid state, both com-
plexes showed similar anticonvulsant activity, prob-
ably due to formation of the same species in the dilute
solutions. The compounds lose salicylate and one
phenantroline ligand in dilute N,N-dimethylformam-
ide (DMF) solution to form [Cu(1,10-phenantro-
line)DMF4]
2?. The results can only be interpolated
to biological systems, since both complexes are
insoluble in water.
Copper palmitate may be useful in preventing skin
photosensitivity induced by porphyrins in patients
who underwent photodynamic therapy. Liposomal
topical cream with Cu-palmitate effectively prevented
skin inflammation in photosensitized rats exposed to
light (Bilgin et al. 2005). Taggar et al. (2006)
successfully prepared liposomal form of anticancer
drugs, topotecan and irinotecan. Copper(II) sulphate
loaded liposomes accumulated and retained drug
molecules due to formation of copper complex inside
the liposome. The authors also reported improved
therapeutic activity of this drug formulation (Taggar
et al. 2006). Sreedhara et al. (2000) reported
Cu-aminoglycosides complexes (of neamine and
kanamycin A) as efficient deoxyribonucleases with
reaction kinetics similar to enzymes. Notably, the
DNA cleavage was achieved by hydrolytic pathway,
without generation of free radicals (Sreedhara et al.
2000). Copper-L-histidine complex (52) is in phase II
clinical trials for treatment of Menkes disease, a
genetic disorder in Cu transport, leading to copper
deficiency (ClinicalTrials.gov 2012).
Copper radioisotopes in nuclear medicine
Natural copper comprises two stable isotopes:
63Cu (69.17 %) and 65Cu (30.83 %). Of 27 known
copper radioisotopes, five are particularly interest-
ing for nuclear medicine: 60Cu, 61Cu, 62Cu, 67Cu,
Table 1 Decay properties
of medically important Cu
radioisotopes
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61Cu 3.33 h – 0.932 (5.5 %)
1.22 (51 %)





62Cu 9.67 min – 2.93 (97.2 %) 2 0.511 (195 %)
64Cu 12.7 h 0.579 (38.5 %) 0.653 (17.6 %) 40 0.511 (35.2 %)
1.35 (0.5 %)
67Cu 61.83 h 0.377 (57 %)
0.468 (22 %)
0.562 (20 %)
– – 0.093 (16.1 %)
0.185 (48.7 %)
0.3 (0.8 %)
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and especially 64Cu. Their nuclear characteristics are
given in Table 1.
Decay characteristics of copper radionuclides make
them suitable for numerous medical applications, such
as Positron Emission Tomography(PET) imaging,
radioimmunological tracing and radiotherapy of can-
cer. For widespread use in medicine of any radioiso-
tope, two factors are essential: availability of the
isotope and effective modes of binding with an
appropriate chemical carrier. Efficient production of
copper isotopes was extensively researched over past
20–30 years, and also many potential chelators were
developed during that time. Methods of production,
applications in nuclear medicine and chelating agents
for copper radioisotopes were reviewed by Blower
et al. (1996), Williams et al. (2005), Rowshanfarzad
et al. (2006), Hao et al. (2009), Wadas et al. (2010),
and Ding et al. (2011).
60Cu
PET is a three dimensional imaging technique which
utilizes simultaneous detection of two oppositely
moving photons, resulting from annihilation of posi-
tron with electron. Positron comes from decay of a
radioisotope incorporated into targeting molecule
which can selectively accumulate in desired tissues,
organs or tumors. The most popular PET tracer is 18F
in a form of 2-deoxy-2-(18F)fluoro-D-glucose. Metallic
radioisotopes have advantage over fluorine-18, as they
can be easily introduced into a targeting molecule by
forming a coordination compound with it. 60Cu is a b?
emitter with decay properties making it possible
candidate for PET tracer. 60Cu can be produced using
small cyclotrons at relatively low costs from 60Ni
target (McCarthy et al. 1999). Relatively high energy
positron and gamma emissions, compared to 62Cu, are




arbazone) (60/61/62/64Cu-ATSM 53), 60/61/62/64Cu-pyr-
uvaldehyde-bis(N4-methylthiosemicarbazone) (60/61/62/64
Cu-PTSM 54) and 60/61/62/64Cu-ethylglyoxal bis(thio-
semicarbazone) (60/61/62/64Cu-ETS 55), are the most
widely studied copper radioisotopes compounds for
use in PET. 60/61/62/64Cu-ATSM and 60/61/62/64Cu-ETS,
due to their specific redox properties, can be useful for
detection and imaging of hypoxic tumor cells. Mech-
anism of action of copper-thiosemicarbazones in
broad outline is as follows: the complex enters cell
where it is spontaneously reduced from Cu(II) to
Cu(I) state, then it can either be reoxidized by
molecular oxygen and diffuse from the cell, or in
hypoxic conditions, it irreversibly decomposes and
stays trapped within cell (Dearling and Packard 2010).
It should be noted that nonradioactive Cu-ATSM has
been recently found to be neuroprotective agent, and
can be used for Parkinson’s disease treatment (Hung
et al. 2012).
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60Cu-ATSM was clinically studied for monitoring
tumor hypoxia in lung and cervical cancer, and found
to be feasible for prediction of tumor response to
therapy (Dehdashti et al. 2003; 2008). Analogous pilot
clinical study for rectal cancer was carried by Dietz
et al. (2008), and also confirmed possible applicability
of 60Cu-ATSM. Chao et al. (2001) suggested that PET
images obtained with 60Cu-ATSM can be used for
intensity-modulated radiation therapy of head and
neck cancer. Since hypoxia of the tumor makes it
resistant to radiotherapy, localization with 60Cu-
ATSM can be used to accurately deliver higher
radiation doses needed for destroying cancer cells
(Chao et al. 2001).
61Cu
61Cu isotope can be produced from zinc, nickel or
cobalt targets. Necessity of highly enriched Ni and Zn
targets or high energy particle beams limited accessi-
bility of 61Cu for biomedical use, until more economic
production methods from natural Zn or Co were
developed (Rowshanfarzad et al. 2006; Hao et al.
2009; Das et al. 2012). Longer half-life than that of
60Cu and 62Cu makes 61Cu better choice for prolonged
imaging of processes with slower kinetics. This isotope,
however, is much less popular in today’s biomedical
studies than the other copper radioisotopes.
61Cu-APTS (2-acetylpyridine thiosemicarbazone)
complex (56), for PET imaging of cancer, was
proposed by Jalilian et al. (2006) Using pyridine
thiosemicarbazone as a ligand, can give additional
antiproliferative activity to the compound, which was
previously observed by other authors (Belicchi-Ferrari
et al. 2005). Hao et al. (2009) found 61Cu-1,4,7,10-
tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)–
human serum albumin to be good blood pool imaging
agent and suggested its application in antiangiogenic
therapy monitoring. Novel approach for therapy of
multinodular goitre, using human chorionic gonado-
tropin (hCG) directly labeled with ionic 61Cu (or some
other b? emitters) was proposed by Maiti et al. (2011)
Initial studies indicates that copper-hCG complex
half-life is shorter than that of a hCG –TSH (thyroid-
stimulating hormone) receptor complex, thus
hyperactive thyroid cells can be destroyed before
internalization of the receptor occurs. More in vitro
and in vivo studies are required to assess usefulness of
this therapy.
62Cu
62Cu has unique properties being almost pure b?
emitter(97.2 %) with short half-life of 9,67 min. It is
easily obtainable from 62Zn/62Cu generators (Fukum-
ura et al. 2006; El-Azony 2011), however relatively
short half-life of parent 62Zn makes these generators
operable for not more than three days. This isotope is
currently the most intensively studied copper radio-
isotope besides 64Cu. 62Cu-PTSM is extensively
researched 62Cu radiopharmaceutical that can be used
for monitoring renal, myocardial and cerebral perfu-
sion. Mathias et al. (1995) observed high species
dependent variability in binding 62Cu-PTSM and
62Cu-ATSM by serum albumin. This can render
problems when predicting behavior of copper thio-
semicarbazones in human system, basing on animal
data. 62Cu-ETS (55) complex is proposed as an
alternative to 60/61/62/64Cu-PTSM for PET perfusion
imaging (Mathias et al. 1995; Green et al. 2007;
Basken et al. 2008). 62Cu-PTSM can be used together
with 62Cu-ATSM to obtain complementary data on
tumor hypoxia and blood circulation in a single PET
session (Black et al. 2008; Wong et al. 2008). 62Cu-
ATSM complex is widely researched for PET imaging
of tumor hypoxia (Laforest et al. 2005; Wong et al.
2008; Minagawa et al. 2011), myocardial (Takahashi
et al. 2001) and cerebral ischaemia (Isozaki et al.
2011).
Other than imaging clinical application of 62Cu was
proposed by Chan et al. (2000) Balloons filled with
62Cu solution have been found effective for intravas-
cular treatment preventing coronary restenosis in
porcine model.
64Cu
The most versatile isotope, 64Cu has found its
application in: in vivo studies of copper metabolism,
radiotracing biodistribution of potential therapeutics,
PET imaging, cancer diagnosing and radiother-
apy(preclinical and clinical trials). Although there
are many methods of 64Cu production, the most
important are those which do not require high energy
beams, unattainable for typical small medical cyclo-
trons (Obata et al. 2003; Szajek et al. 2005; Le et al.
2009). However, such methods need enriched targets,
which increase overall costs. Using natural zinc as
a starting material, 64Cu can be produced with
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reasonable purity, but many highly radioactive
byproducts of the reaction need to be removed and
handled properly (Bonardi et al. 2003). 64Cu half-life
allows it to be transported to locations remote of the
production site, and currently this isotope is commer-
cially available from several producers around the
world.
Similarly to 60Cu, 61Cu and 62Cu isotopes, 64Cu-
ATSM is subject to many ongoing research as
selective tumor hypoxia imaging agent. It is in phase
II clinical trials for PET/CT monitoring of therapeutic
progress in patients with cervical cancer (Clinical-
Trials.gov 2012). Similar compound, 64Cu-ATSE
(Cu-diacetyl-bis(N4-ethylthiosemicarbazone)) (57),
has wider tissue-oxygenation level specificity than
64Cu-ATSM. Increased uptake of 64Cu-ATSM by cell
cultures occurs between oxygen concentration
0.1–0.5 %, while for the 64Cu-ATSE it happens
between 0.1 and 5 %, which can make it more suitable
imaging agent for less extreme hypoxias in myocardial
and nervous tissues (McQuade et al. 2005). Because
64Cu is also b- emitter, 64Cu-bis-thiosemicarbazones
can be used for radiotherapy. Yoshii et al. (2011)
showed that 64Cu-ATSM administration reduces vol-
ume and metastatic abilities of Colon-26 tumor in
mice. Advantage of this treatment over other cancer
therapies comes from the fact that 64Cu-ATSM
reduced number of CD133? (prominin-1 positive)
cells within tumor. CD133? cells contributes to
ineffectiveness of cancer therapies, being chemo-
and radioresistant, and also highly tumorigenic. 64Cu-
ATSM decreases number of CD133? cells not by
specific interactions, but rather by accumulating
within regions of tumor with high abundance of
CD133? cells, which results in higher doses of
radiation in that areas (Yoshii et al. 2011). To increase
cytotoxic effectiveness of 64Cu-ATSM, Aft et al. 2003
administered it together with 2-deoxy-D-glucose to
mice bearing EMT-6 mammary carcinoma cell line.
2-deoxyglucose accumulates in tumor cells and
potentiate effects of radiation therapy. In the study,
pretreatment with 2-deoxyglucose increased tumor
uptake of 64Cu-ATSM. Continuing daily administra-
tion (2 mg/g) of 2-deoxyglucose after single dose of
64Cu-ATSM increased survival time of the animals
(Aft et al. 2003). Other than thiosemicarbazone
ligands for 64Cu, based on 2-nitroimidazole (another
hypoxia-selective compound), were evaluated in vivo
by Engelhardt et al. (2002) and were found suitable for
imaging of tumor hypoxia. More recently, Bonnitcha
et al. (2010) explored an idea to conjugate thiosemi-
carbazones with nitroimidazoles, since these com-
pounds have the same biological targets. Copper
complexes of the ligands (58) synthesized by the
authors showed excellent selectivity for hypoxic
EMT-6 cells.
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PET and SPECT (Single-Photon Emission Computed
Tomography) techniques are used in mapping brain
activity in behavioral studies on animals and humans.
Many social behaviors cannot be monitored in immobi-
lized test subjects. Compounds containing long living b?
emitters, such as 64Cu-PTSM, are suitable for monitoring
cerebral perfusion in freely moving subjects (Holschne-
ider and Maarek 2004). 5,13-dioximino-6,9,9,12-tetra-
methyl-7,11-diazaheptadeca-6,11-diene complex of
copper-64 (59) synthesized by Packard et al. (2002) can
be potentially used as myocardial perfusion imaging
agent, and also for multidrug resistance screening. The
complex shows tumor uptake similar to 99mTc-MIBI
(hexakis(2-methoxy-2-methylpropylisonitrile) techne-
tium (99mTc)), a compound used for predicting drug
resistance of tumors associated with P-glycoprotein
expression (Packard et al. 2002).
64Cu labeled peptides for targeted cancer therapy/
imaging are one of the largest group of copper
radiopharmaceuticals currently researched. They are
built of a targeting peptide such as bombesin or
octreotide analogue, a linker, and a bifunctional chelator
(BFC), commonly tetraazamacrocycle derivate, like
TETA or DOTA (Fig. 5). The peptide binds to a specific
receptor expressed by cancer cells while copper isotope-
BFC moiety allows localization of the tumor by positron
emission detection. b- radiation of 64Cu can also be
exploited for selective irradiation of malignant cells.
Attractiveness of peptides for targeted radiotherapy, in
comparison to monoclonal antibodies, comes from their
good tissue distribution, fast clearance, low immuno-
genicity, and inexpensive, automated production. By
modifying amino acid composition of a peptide, one can
adjust hydrophobicity, pKa, resistance to proteolysis,
and other parameters of the peptide to form a suitable
diagnostic agent. Table 2 lists the most popular peptides
which were modified to be used with 64Cu for cancer
imaging and therapy.
Zhang et al. approached other than oncological use
of such type of compounds. They designed a 64Cu-
labeled peptide targeting neutrophils that can be used
for non-invasive detection of acute, neutrophilic
inflammation (Zhang et al. 2007c).
Fig. 5 DOTA and TETA, the two most common bifunctional
chelators used for labeling biomolecules
Table 2 Targeting peptides for 64Cu PET tracers
Peptide Properties Cancer type Reference





Yang et al. (2006), Hoffman and Smith (2009),
Prasanphanich et al. (2009), and Lane et al. (2010)
Tyr3-octreotide Somatostatin analog Neuroendocrine
tumors








Chen et al. (2004), Wei et al. (2009), Galibert et al.
(2010), and Jin et al. (2011)
VIP Vasoactive intestinal peptide Breast
Colorectal
Prostate
Thakur et al. (2004) and Zhang et al. (2007a)
PACAP Pituitary adenylate cyclase activating
peptide
Breast cancer Zhang et al. (2007a)
a-MSH Melanocyte stimulating hormone Melanoma Cheng et al. (2007) and Wei et al. (2007)
Ac-Cys-
ZEGFR:1907
Affibody for epidermal growth factor
receptor
Various types (Miao et al. (2010)
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Monoclonal antibodies (mAbs) are vast group of
biotechnologically produced proteins, with constantly
rising number of applications in immunotherapy,
targeted drug delivery, and in vivo/in vitro diagnostics.
In this compounds group, we can distinguish intact
immunoglobulins (murine, chimeric, humanized and
human) and fragments of heavy chain antibodies
(nanobodies, domain-deleted mAbs, hypervariable
domain region peptides, minibodies, affibodies and
other). Transforming mAbs into radiopharmaceuticals
is relatively simple. When using radioisotopes such as
iodine-131 or fluorine-18, small molecule labeled with
atom/atoms of the isotope, coupled with a linker is
attached to amino acids residues (mostly randomly) of
the antibody. Similarly, if using metallic radioisotopes,
a bifunctional chelator with linker is coupled to the
antibody, then solution of the radioisotope salt is added
to form a complex. In most cases, mAbs for radiother-
apy can be formulated in a convenient form of kits, for
preparation of the radiopharmaceutical right before
administration to a patient (Reilly 2010). Examples of
64Cu-labeled antibodies for PET imaging are trast-
uzumab (breast cancers expressing human epidermal
growth factor receptor 2 or HER2, in clinical trials)
(Sampath et al. 2010; ClinicalTrials.gov 2012), 12A8
(c-kit expressing tumors) (Yoshida et al. 2011),
etaracizumab (antibody against human avb3 integrin)
(Cai et al. 2006), cetuximab (targeting EGFR-epider-
mal growth-factor receptor expressing tumors) (Li et al.
2008).
67Cu
67Cu is the longest living copper radioisotope and also
one of the most difficult to produce, since it requires
fast neutron flux reactor or high-energy proton beams
and costly 68Zn target (Katabuchi et al. 2008). This
isotope of copper, owning to interesting decay prop-
erties, is widely acknowledged as potentially useful
for radioimmunotherapy, but due to limited availabil-
ity, the number of research that actually use this
isotope is low, compared to other Cu isotopes.
Dynamic growth of radioimmunotherapy, can
increase demand for this isotope. Medvedev et al.
(2012) reported an attempt to produce 67Cu in a larger
scale, which gives perspectives for wider commercial
availability of the isotope in the near future.
The possibility to change imaging agents into thera-
peutics is very attractive in copper radiopharmaceuticals.
This can be achieved by replacing positron emitting
nuclides of 60/61/62/64Cu with electron emitting 67Cu,
without changing pharmacokinetics of the com-
pounds. Since biodistribution of 60/61/62/64Cu-labeled
substances can be monitored using PET, the data can
be directly translated to 67Cu compounds (Cai et al.
2006). 67Cu is one of the best suited isotopes for
radioimmunotherapy, because of its half-life long
enough to allow good biodistribution within tumor
(similar to biological half-life of many mAbs),
relatively low gamma radiation abundance (lower
whole body dose for patient and safer for medical
personnel), higher tumor uptake (compared to iodine-
131) and simple radiolabeling procedure (Carrel et al.
1997; Delaloye et al. 1997; DeNardo et al. 2000;
Novak-Hofer and Schubiger 2002). Examples of
67Cu-labelled mAbs are chCE7, an anti-L1-cell adhe-
sion molecule antibody for neuroblastoma, ovarian,
and some renal carcinoma therapy (Zimmermann
et al. 1999; Zimmermann et al. 2003; Knogler et al.
2007), Lym-1 for non-Hodgkin’s lymphoma (De-
Nardo et al. 1999; Mirick et al. 1999; DeNardo et al.
2000), C595 an anti-MUC1 mucin antibody for
bladder cancer treatment (Hughes et al. 2000).
Possible applications of 67Cu are not limited to
radiotherapy; gamma radiation of the isotope can be
used for Single-Photon Emission Computed Tomog-
raphy (SPECT) (Engelhardt et al. 2002).
To date, no radiopharmaceutical containing copper
isotope is approved for use in humans. Although many
promising results were obtained during studies on Cu
radiopharmaceuticals, several problems also emerged.
Therefore current research have to focus on overcom-
ing these obstacles.
• Of five discussed isotopes, only 62Cu can be obtained
from generator. 64Cu and 67Cu have half-life long
enough to be transported from remote locations, but
60Cu and 61Cu require cyclotron access. Therefore,
availability of copper radioisotopes is still the main
limitation for their wider application.
• High energy of emitted positrons of 60/61/62Cu in
relative to standard PET imaging radionuclide 18F,
is cause of the loss of spatial resolution of the
resulting image. Recovery of three-dimensional
data, when imaging with high-resolution PET
camera, requires development of dedicated anal-
ysis algorithms (Ruangma et al. 2006; Liu et al.
2009).
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• Burgman et al. (2005) found that 64Cu-ATSM
shows cell line dependent pharmacokinetics,
therefore obtained imaging data in some cases
can be irrelevant to tumor hypoxia.
• Theoretical calculations made by O’Donoghue
et al. (1995) indicate that tumors 2–3 mm in
diameter are optimal for effective treatment with
67Cu. Thus, usefulness of this isotope in cancer
therapy is limited only to small tumors.
• In vivo studies of first generation of Cu-radioiso-
tope labeled peptides showed poor stability of
these compounds and liberation of copper from the
complexes (Mirick et al. 1999; Bass et al. 2000;
Boswell et al. 2004; Sprague et al. 2006). Mon-
ocycylic tetraazamacrocycle based BFCs, such as
TETA or DOTA, are not sufficiently inert in blood
serum and should not be considered in designing
new copper radiopharmaceuticals. Cross-bridged
macrocycles are currently replacing other type
chelating agents (Ma et al. 2002; Boswell et al.
2004; Anderson et al. 2008).
• Radiolabeled peptides and antibodies show high
retention in kidneys which receive larger dose of
radiation than other organs. To prevent kidneys
damage, either dose of the radiopharmaceuticals
has to be reduced, which can lead to ineffective-
ness of the therapy, or additional substances
reducing renal uptake need to be administered
simultaneously (Vegt et al. 2010).
• Main problem of radioimmunotherapy with intact
mAbs is their heterogenous biodistribution within
solid tumors, resulting in insufficient dose delivered
to some of the malignant cells. Therefore, it is
necessary to develop other strategies for use of
monoclonal antibodies in cancer radiotherapy, such
as pretargeting techniques, reduction of the size of
the antibody or increasing capillary permeability
(Tempero et al. 2000; Goldenberg and Sharkey
2006; Reilly 2006; Thurber et al. 2008).
Copper in nanomedicine
Past ten to twenty years are the time of rapid progress
in nanotechnology and nanomedicine. Term nano-
technology generally refers to chemistry and physics
of 1–100 nm sized particles, however, the term has
become overused for synthesis and rational design of
large molecule compounds, polymeric and colloidal
materials. Reduction of size has opened new possibil-
ities for use of metallic elements and their compounds
in medicine. Metal nanosized particles or quantum
dots (colloidal metal chalcogenides, consisting of core
and external shell), exhibit novel physicochemical
properties that cannot be observed in macroscale.
Cations of metal can be complexed with multi-part
macromolecular ligands, so the resulting chemical
constructs can overcome limitations in distribution,
bioavailability and binding specificity of simple
compounds (Balogh et al. 2007; Studer et al. 2010;
Gunawan et al. 2011; Webster 2011).
Biocidal properties of copper and its compounds
have been known since ancient times and include
antibacterial, antifungal, molluscicidal, nematocidal,
antiviral and other (Borkow and Gabbay 2005).
Mechanism of antimicrobial action of copper is
complex and not fully understood; Cu2? ions disrupt
permeability of cell’s membrane, cause lipid perox-
idation and proteins inactivation (Ohsumi et al. 1988;
Nan et al. 2008; Raffi et al. 2010; Wu et al. 2011).
Antibacterial properties of nanometer sized copper
particles come mainly from ions liberation, however,
the size plays important role in adsorption on
bacterial cell surface (Raffi et al. 2010). It is possible
to construct polymers doped with metallic or ionic
copper. Such polymers can be used to make dressings,
sutures, bandages and other medical materials with
anti-infection, anti-inflammatory and healing-accel-
erating properties (Zhang et al. 2007b; Borkow et al.
2009; Grace et al. 2009; Sheikh et al. 2011). Similarly
to copper nanoparticles, copper oxide nanoparticles
are known to be nonspecifically cytotoxic. The
activity comes from intracellular, amino acids med-
iated liberation of copper ions, which form com-
plexes inducing formation of reactive oxygen species
(Studer et al. 2010; Gunawan et al. 2011). Socks
impregnated with copper oxide are effective in
treatment of tinea pedis (fungal infection caused by
Trichophyton genus) (Zatcoff et al. 2008). The socks
can also be used for preventing so called hand and
foot syndrome in capecitabine treated patients; rele-
vant clinical studies have started (ClinicalTrials.gov
2012). Respiratory face masks with CuO offer very
good protection against human influenza virus H1N1
(Borkow et al. 2010). A number of copper containing
textiles and materials are already commercially
available.
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Most of today’s contraceptive intrauterine devices
(IUDs) contain metallic copper in a form of sheet or
wire. Rapid release of cupric ions in the first few days
after implantation of IUD can cause adverse effects
such as pelvic inflammatory disease, bleeding and
expulsion (Timonen 1976; Farley et al. 1992; Mora
et al. 2002). Low density polyethylene-copper nano-
particles composites show sustained, zero-order
kinetic of copper ions release, therefore can be used
to replace conventional IUDs (Cai et al. 2005).
Bhattacharya et al. (2006) suggested that metal
nanoparticles can be used for selective precipitation
and conformational alterations in proteins. They found
that copper nanoparticles clusters precipitate with
human hemoglobin mutant HbE, and can serve as a
screening agent for hemoglobinopathies such as
b-thalassemia (Bhattacharya et al. 2006). Photother-
mal ablation is one of the newest methods of cancer
treatment. Microscopic spheres, built of dielectric core
and metal shell, accumulate passively or actively
(after functionalization with antibodies) in tumors, and
destroy them with heat which the particles emit when
excited by near infrared light. Modified gold nano-
particles are commonly researched for this purpose
(Cai et al. 2008; Chen et al. 2010; Choi et al. 2011). As
an alternative to costly gold, Li et al. (2010) proposed
copper sulfide nanoparticles which have very good
optical properties, minimal cytotoxicity and low
production costs.
Quantum dots (QDs) are nanoparticles that have
received much attention in medicine as tumor detec-
tion and imaging agents (Zhang et al. 2008). Coating
QDs with amphiphilic polymers and functionalizing
their surface with antibodies, peptides, oligonucleo-
tides or small-molecule drugs can be done in order to
facilitate targeted delivery and to reduce non-specific
binding of these nanoparticles (Gao et al. 2005). To
achieve quantitative imaging of tumor vasculature in
deep tissues, Chen et al. (2008) successfully developed
dual optical/PET tracer by functionalizing QDs with
64Cu-DOTA. There is little known, however, about
QDs toxicity, which is an important matter, since most
of QDs contain hazardous elements such as cadmium,
selenium, tellurium and arsenic (Rzigalinski and
Strobl 2009). Oxidation of CdSe cores and liberation
of Cd2? ions take place even in coated QDs (Derfus
et al. 2004). Development of cadmium-free QDs could
be a solution to this problem. Using copper-indium
sulfide based QDs, Yong et al. (2010) achieved very
promising results for novel, non-toxic, highly sensitive
cancer imaging agent.
Superparamagnetic iron oxide nanoparticles are
another type of nanostructures that can be function-
alized in a similar manner to quantum dots. Their
magnetic properties can be used for magnetic reso-
nance imaging (MRI) of cancer. Several authors have
exploited the idea of dual MRI/PET tracing to obtain
complementary data on tumor localization, using
64Cu-DOTA labeled iron oxide particles (Jarrett
et al. 2008; Lee et al. 2008).
Carbon nanotubes (CNTs) have been successfully
applied in various areas of science, technology and in
medicine. CNTs are very promising as multifunctional
platforms for targeted therapy and imaging. A good
example of such CNT construct was synthesized and
tested in vivo by Liu et al. (2007). The authors used
single walled CNTs coated by phospholipids-poly-
ethyleneglycol for water solubility, functionalized
with RGD peptide for targeted delivery and labeled
with 64Cu-DOTA for PET imaging. The resulting
construct showed good biodistribution and selectivity
towards avb3-positive cancer (Liu et al. 2007). CNTs
do not cause acute toxicity, but there is no sufficient
knowledge yet about long term exposure and distant
effects on human health (Liu et al. 2008; Firme and
Bandaru 2010).
Medical sensing devices are very helpful for
diagnosing and for monitoring patient’s pharmaco-
therapy. Various authors have prepared copper nano-
particles-based electrodes for determination of
glucose and other carbohydrates (Male et al. 2004;
Xu et al. 2006; Jiang and Zhang 2010), drugs such as
sotalol or acetaminophen (Boopathi et al. 2004; Heli
et al. 2009) and amino acids (Zen et al. 2004; Dong
et al. 2010). Cai et al. (2003) demonstrated that gold
covered copper nanoparticles, functionalized with
oligonucleotides can be used for electrochemical
detection of characteristic DNA sequences present in
pathogenic microorganisms or mutated genes. Nano-
crystals of CuS conjoined with immunoglobulin, was a
part of multiple protein detection system, developed
by Liu et al. (2004) The system allows sensitive,
simultaneous, electrochemical detection of proteins,
and can be used to construct novel diagnosing devices.
Advances in modern polymer sciences have opened
new horizons for targeted drug delivery systems and
diagnostic tools development. One of the most prom-
ising and extensively studied groups of compounds are
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dendrimers. Dendrimers are globular shaped,
branched polymers with fixed molecular weight that
can be modified with various functional groups on
their surface. Moreover, there are empty spaces
between polymer branches that can be fitted with
small molecules. There has been a lot of interest in
dendrimers as potential drug carriers and artificial
enzymes (Kofoed and Reymond 2005). By utilizing
the ‘click chemistry’, dendrimers can be easily
synthesized and functionalized. Dijkgraaf et al.
(2007) used this approach to synthesize dendrimers
conjoined with RGD peptides and DOTA, for use in
tumor imaging after complexation with radionuclides
such as 111In or 64Cu. Some dendritic copper com-
plexes were tested for antimicrobial activity by Refat
et al. (2009) and showed moderate strength of action
on selected microorganisms. Poly(amidoamine)-
Schiff base dendrimers synthesized by Zhao et al.
(2010) form multinuclear complexes with CuCl2,
which show good antiproliferative activity against
MOLT-4 leukemia and cisplatin resistant MCF-7
breast cancer cells.
There are known several dendritic copper com-
plexes that exhibit catalytic properties ranging from
Lewis acid catalyzed addition reactions to free radical
induced hydrolysis (Yang et al. 2003; Fujita et al.
2006; Kao et al. 2011). One particular example is
nuclease activity of copper(II) complexes of a pyri-
dine-modified poly(amidoamine) dendrimers. These
compounds have ability to induce formation of oxygen
radicals leading to cleavage of nucleic acid strand
(Kao et al. 2011). Artificial nucleases can be used as
anticancer drugs or for sequencing DNA and RNA. On
the other hand, natural recombined nucleases, such as
dornase alpha, are used in lung diseases (cystic
fibrosis, chronic bronchitis), reducing viscosity of
mucus in respiratory tract. An unexplored to date
possibility is the use of dendritic deoxyribonucleases
as potential therapeutics in aforementioned diseases.
Dendrimers can be also used as protective colloids,
acting as templates, in the synthesis of copper nano-
particles with regular shape and size (Jin et al. 2008).
Another type of polymeric nanoparticles are aggre-
gates formed by controlled self assembly of diblock
amphiphilic copolymers. Many shapes can be achieved,
such as spheres, rods, discs, helices, tubes, but the
spheres are generally the easiest to attain and are also the
most versatile. These structures can be stabilized by
cross-linking and variously functionalized (O’Reilly
et al. 2006). Rossin et al. (2005) synthesized shell cross-
linked nanoparticles with folic acid and 64Cu-TETA
moieties attached on the surface which can be used for
early diagnosing and therapy of tumors overexpressing
folate receptor.
Binding copper(II) with small peptides in some
cases can induce formation of nanoaggregates of
resulting complexes (Yang et al. 2008; Ren et al. 2008;
Li et al. 2011). Complexing with metal ions can
reinforce the biological activity of various peptides
because such complexes have more rigid structure,
and therefore less possible conformations (Tian and
Bartlett 1996; Taraszka et al. 2000; Salvati et al.
2008). Li et al. (2011) synthesized four Cu(II)-RGD-
octapeptides and found that these compounds have
significantly higher anti-thrombotic activity in vivo
than free RGD-octapeptides. Similar results are
reported in the paper by Ren et al.(2008), in which
several tripeptide-Cu(II) complexes were found to
have increased thrombolytic activity both in vivo and
in vitro, along with additional vasodilatation effect.
Conclusion
Versatility of copper and its compounds has given it a
strong position in development of new pharmaceuticals.
Although currently there are only a few applications of
Cu in medicine, numerous ongoing studies will most
likely result in novel uses in the future. Copper
radiopharmaceuticals will be probably the first to be
approved for clinical use. Cu-containing materials and
nanomaterials also hold a great promise and should soon
find many applications in various fields of medicine.
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